Author Archives: admin


Stem Cell Clinic > Articles by: admin

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

By Stell Cell Research

DEER PARK, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has completed its previously announced asset purchase of Increlex® (mecasermin injection) from Ipsen S.A. (“Ipsen”). Increlex® is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD).

Read the original post:
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

By Stell Cell Research

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company’s oral C5aR inhibitor, INF904.

Read the rest here:
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Novo Nordisk A/S – share repurchase programme

By Stell Cell Research

Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.

Here is the original post:
Novo Nordisk A/S - share repurchase programme

Lowell Farms Inc. Appoints Philippe Faraut as Chief Financial Officer

By Stell Cell Research

SALINAS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born cannabis company with advanced production capabilities including extraction, manufacturing, and distribution, announces the appointment of Philippe Faraut as Chief Financial Officer of the Company, effective immediately.

Read more:
Lowell Farms Inc. Appoints Philippe Faraut as Chief Financial Officer

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

By Stell Cell Research

SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance’s common stock to forty-eight new, non-executive employees.

More:
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025

By Global News Feed

LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced that it will hold its annual general and special meeting of shareholders (the “Meeting”) on Friday, January 10, 2025, at 1:00pm ET. Due to the recent postal strike in Canada, the Meeting, which had originally been scheduled to be held on January 7, 2025, at 1:00pm ET, was postponed so that Sernova and its agents are able to complete the mailing of its meeting materials through Canada Post to meet regulatory requirements.

View original post here:
Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025

→←